Deutsche Bank maintained a Hold rating on Sarepta Therapeutic (NASDAQ: SRPT) with a price target of $24. Yesterday Sarepta said ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View

BofA/Merrill Lynch Downgrades Sarepta Therapeutic (SRPT) to NeutralMay 21, 2015 7:38 AM Cowen Maintains Neutral View on Sarepta (SRPT) Despite Rolling NDA for EteplirsenMay 20, 2015 9:01 AM Sarepta (SRPT) PT Raised to $25 at Wedbush on Go-Ahead for Eteplirsen NDAMay 20, 2015 7:30 AM Piper Jaffray Remains on Sidelines with Sarepta (SRPT) Despite Rolling NDA For EteplirsenMay 20, 2015 7:08 AM UPDATE: Canaccord Genuity Upgrades Sarepta Therapeutic (SRPT) to BuyMay 20, 2015 6:54 AM SunTrust Upgrades Sarepta Therapeutic (SRPT) to BuyMay 20, 2015 6:53 AM Sarepta Therapeutic (SRPT) PT Raised to $45 at Roth CapitalMay 20, 2015 6:23 AM Sarepta (SRPT) PT Boosted to $34 at Baird Amid Rolling NDA SubmissionMay 20, 2015 6:19 AM Sarepta Therapeutics (SRPT) Will Initiate Rolling NDA for EteplirsenMay 19, 2015 4:00 PM Sarepta Therapeutics Announces Plans to Submit Rolling NDA for Eteplirsen following Today’s Pre-NDA Meeting with the FDAMay 19, 2015 4:00 PM